HRP20220892T1 - Pripravak rmp i postupci upotrebe - Google Patents
Pripravak rmp i postupci upotrebe Download PDFInfo
- Publication number
- HRP20220892T1 HRP20220892T1 HRP20220892TT HRP20220892T HRP20220892T1 HR P20220892 T1 HRP20220892 T1 HR P20220892T1 HR P20220892T T HRP20220892T T HR P20220892TT HR P20220892 T HRP20220892 T HR P20220892T HR P20220892 T1 HRP20220892 T1 HR P20220892T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- rmp
- erythrocytes
- preparation according
- internal density
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 4
- 238000000034 method Methods 0.000 title claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 6
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 4
- 108010022752 Acetylcholinesterase Proteins 0.000 claims 4
- 229940022698 acetylcholinesterase Drugs 0.000 claims 4
- 230000000740 bleeding effect Effects 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 206010073391 Platelet dysfunction Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 229940072645 coumadin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000000684 flow cytometry Methods 0.000 claims 1
- 239000003055 low molecular weight heparin Substances 0.000 claims 1
- 229940127215 low-molecular weight heparin Drugs 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 108010014806 prothrombinase complex Proteins 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000003868 thrombin inhibitor Substances 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (15)
1. Pripravak, naznačen time što se sastoji od mikročestica dobivenih od eritrocita (RMP) koje pokazuju aktivnost acetilkolin-esteraze (AchE) manju od 350 pmol/min/106 čestica/µl.
2. Pripravak u skladu s patentnim zahtjevom 1, naznačen time što RMP pokazuju aktivnost acetilkolin-esteraze (AchE) manju od 200 pmol/min/106 čestica/µl.
3. Pripravak u skladu s patentnim zahtjevom 1 ili patentnim zahtjevom 2, naznačen time što 20%-50% RMP u pripravku display fosfatidilserin.
4. Pripravak u skladu s patentnim zahtjevom 3, naznačen time što 30%-45% RMP u pripravku pokazuje fosfatidilserin.
5. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što pripravak skraćuje vrijeme do početnog stvaranja ugruška, kao što je izmjereno tromboelastografijom (TEG) u punoj krvi i plazmi za najmanje dvije minute.
6. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je srednji promjer RMP 0,40-0.6 µm.
7. Pripravak u skladu s patentnim zahtjevom 6, naznačen time što je srednji promjer RMP 0,40-0,5 µm.
8. Pripravak u skladu s patentnim zahtjevom 7, naznačen time što je srednji promjer RMP 0,47 µm.
9. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što je unutarnja gustoća RMP manja od 3,5% unutarnje gustoće cijelih eritrocita.
10. Pripravak u skladu s patentnim zahtjevom 9, naznačen time što je unutarnja gustoća RMP 0,5-3,0% unutarnje gustoće cijelih eritrocita, kao što je izmjereno signalom bočnog rasapa kod protočne citometrije.
11. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što se RMP proizvodi protiskivanjem eritrocita kroz otvor kako bi se dobilo eritrocite s rupturom, te zatim fragmentiranjem eritrocita s rupturom bombardiranjem na čvrstu površinu.
12. Pripravak u skladu s bilo kojim od patentnih zahtjeva 1-11, namijenjen upotrebi u postupku liječenja prekomjernog krvarenja kod subjekta, naznačen time što se postupak sastoji u primjeni pripravka na subjektu.
13. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je prekomjerno krvarenje posljedica trombocitopenije ili disfunkcije trombocita.
14. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je disfunkcija trombocita posljedica liječenja lijekovima.
15. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je prekomjerno krvarenje posljedica antikoagulansa, izborno Coumadina, niskomolekulskog heparina, inhibitora protrombinaznog kompleksa, inhibitora čimbenika FXa ili inhibitora trombina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428155P | 2016-11-30 | 2016-11-30 | |
| PCT/US2017/063700 WO2018102409A2 (en) | 2016-11-30 | 2017-11-29 | Rmp composition and methods of use |
| EP17876484.1A EP3548092B1 (en) | 2016-11-30 | 2017-11-29 | Rmp composition and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220892T1 true HRP20220892T1 (hr) | 2022-10-14 |
Family
ID=62241842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220892TT HRP20220892T1 (hr) | 2016-11-30 | 2017-11-29 | Pripravak rmp i postupci upotrebe |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11241457B2 (hr) |
| EP (1) | EP3548092B1 (hr) |
| JP (2) | JP2020508963A (hr) |
| KR (2) | KR20240049569A (hr) |
| CN (1) | CN110799199B (hr) |
| AU (1) | AU2017367084B2 (hr) |
| BR (1) | BR112019010981A2 (hr) |
| CA (1) | CA3045144A1 (hr) |
| DK (1) | DK3548092T3 (hr) |
| ES (1) | ES2924134T3 (hr) |
| HR (1) | HRP20220892T1 (hr) |
| HU (1) | HUE059678T2 (hr) |
| IL (1) | IL266957B (hr) |
| LT (1) | LT3548092T (hr) |
| MX (1) | MX2019006354A (hr) |
| PL (1) | PL3548092T3 (hr) |
| PT (1) | PT3548092T (hr) |
| RS (1) | RS63537B1 (hr) |
| RU (1) | RU2768743C2 (hr) |
| SI (1) | SI3548092T1 (hr) |
| WO (1) | WO2018102409A2 (hr) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529561A (en) | 1978-03-24 | 1985-07-16 | The Regents Of The University Of California | Method for producing liposomes in selected size range |
| US5332578A (en) | 1989-04-14 | 1994-07-26 | Prp, Inc. | Platelet membrane microparticles |
| AU702669B2 (en) * | 1994-02-14 | 1999-03-04 | Kirin Brewery Company, Limited | Protein having TPO activity |
| US5690963A (en) | 1995-06-30 | 1997-11-25 | The United States Of America As Represented By The Secretary Of The Navy | Freeze dried red blood cells |
| IL142864A0 (en) | 1998-11-12 | 2002-03-10 | Novolytics Inc | Compositions and methods for producing vascular occlusion |
| US20030040480A1 (en) | 2001-07-20 | 2003-02-27 | Rasmus Rojkjaer | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides |
| US7294455B2 (en) * | 2003-05-16 | 2007-11-13 | The University Of North Carolina At Chapel Hill | Fixed-dried platelets cross-linked to protein |
| US7811558B2 (en) | 2004-08-12 | 2010-10-12 | Cellphire, Inc. | Use of stabilized platelets as hemostatic agent |
| US9155764B1 (en) * | 2004-12-07 | 2015-10-13 | University Of Miami | Expanded utility of red-cell derived microparticles (RMP) for treatment of bleeding |
| PL1819230T3 (pl) | 2004-12-07 | 2013-02-28 | Univ Miami | Makrocząstki pochodzące z czerwonych krwinek jako czynniki hemostatyczne do kontrolowania krwotoku i do leczenia zaburzeń krwawienia |
| US20080057505A1 (en) | 2006-07-14 | 2008-03-06 | Ping Lin | Methods and compositions for detecting rare cells from a biological sample |
| JP5819444B2 (ja) * | 2011-01-28 | 2015-11-24 | ユニバーシティー・オブ・マイアミＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍｉａｍｉ | 出血の処置のための赤血球由来微粒子（ｒｍｐ）の拡大された有用性 |
| US10004764B2 (en) | 2013-11-07 | 2018-06-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Red blood cell membrane-derived microparticles and their use for the treatment of lung disease |
| CN107405391B (zh) * | 2015-03-04 | 2021-03-19 | 罗切斯特大学 | 治疗外伤患者中的出血的血小板微粒的全身和局部应用 |
-
2017
- 2017-11-29 US US16/465,054 patent/US11241457B2/en active Active
- 2017-11-29 ES ES17876484T patent/ES2924134T3/es active Active
- 2017-11-29 HU HUE17876484A patent/HUE059678T2/hu unknown
- 2017-11-29 KR KR1020247007757A patent/KR20240049569A/ko not_active Application Discontinuation
- 2017-11-29 CN CN201780074200.3A patent/CN110799199B/zh active Active
- 2017-11-29 JP JP2019529843A patent/JP2020508963A/ja active Pending
- 2017-11-29 LT LTEPPCT/US2017/063700T patent/LT3548092T/lt unknown
- 2017-11-29 CA CA3045144A patent/CA3045144A1/en active Pending
- 2017-11-29 AU AU2017367084A patent/AU2017367084B2/en active Active
- 2017-11-29 MX MX2019006354A patent/MX2019006354A/es unknown
- 2017-11-29 KR KR1020197018762A patent/KR20190099436A/ko not_active IP Right Cessation
- 2017-11-29 RU RU2019120008A patent/RU2768743C2/ru active
- 2017-11-29 WO PCT/US2017/063700 patent/WO2018102409A2/en unknown
- 2017-11-29 PT PT178764841T patent/PT3548092T/pt unknown
- 2017-11-29 BR BR112019010981A patent/BR112019010981A2/pt unknown
- 2017-11-29 SI SI201731199T patent/SI3548092T1/sl unknown
- 2017-11-29 EP EP17876484.1A patent/EP3548092B1/en active Active
- 2017-11-29 PL PL17876484.1T patent/PL3548092T3/pl unknown
- 2017-11-29 DK DK17876484.1T patent/DK3548092T3/da active
- 2017-11-29 HR HRP20220892TT patent/HRP20220892T1/hr unknown
- 2017-11-29 RS RS20220717A patent/RS63537B1/sr unknown
-
2019
- 2019-05-28 IL IL266957A patent/IL266957B/en unknown
-
2022
- 2022-10-28 JP JP2022173557A patent/JP2023017857A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RS63537B1 (sr) | 2022-09-30 |
| IL266957B (en) | 2022-05-01 |
| RU2768743C2 (ru) | 2022-03-24 |
| RU2019120008A (ru) | 2021-01-13 |
| MX2019006354A (es) | 2019-10-21 |
| CN110799199A (zh) | 2020-02-14 |
| KR20240049569A (ko) | 2024-04-16 |
| RU2019120008A3 (hr) | 2021-03-09 |
| WO2018102409A2 (en) | 2018-06-07 |
| EP3548092A4 (en) | 2021-01-27 |
| CA3045144A1 (en) | 2018-06-07 |
| HUE059678T2 (hu) | 2022-12-28 |
| SI3548092T1 (sl) | 2022-10-28 |
| PL3548092T3 (pl) | 2022-10-10 |
| EP3548092B1 (en) | 2022-07-06 |
| BR112019010981A2 (pt) | 2019-10-15 |
| AU2017367084B2 (en) | 2023-11-23 |
| IL266957A (en) | 2019-07-31 |
| ES2924134T3 (es) | 2022-10-04 |
| JP2020508963A (ja) | 2020-03-26 |
| US11241457B2 (en) | 2022-02-08 |
| JP2023017857A (ja) | 2023-02-07 |
| CN110799199B (zh) | 2024-01-30 |
| AU2017367084A1 (en) | 2019-06-20 |
| PT3548092T (pt) | 2022-08-09 |
| KR20190099436A (ko) | 2019-08-27 |
| WO2018102409A3 (en) | 2019-12-05 |
| US20190321406A1 (en) | 2019-10-24 |
| DK3548092T3 (da) | 2022-08-01 |
| LT3548092T (lt) | 2022-10-10 |
| EP3548092A2 (en) | 2019-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mooberry et al. | Microparticle analysis in disorders of hemostasis and thrombosis | |
| WO2006116361A3 (en) | Methods and devices for monitoring platelet function | |
| JP2016534714A5 (hr) | ||
| GB2546432A (en) | Apertured fibrous structures and methods for making same | |
| WO2004081579A3 (en) | Protocol for monitoring platelet inhibition | |
| WO2014165634A3 (en) | Three-dimensional networks comprising nanoelectronics | |
| JP2016517360A5 (hr) | ||
| WO2014122654A3 (en) | Hybrid nanopores and uses thereof for detection of analytes | |
| WO2014121126A3 (en) | Methods and systems for assessing sample behavior in a flow cytometer | |
| WO2012003307A3 (en) | Filaments comprising an active agent nonwoven webs and methods for making same | |
| AR088572A1 (es) | Metodos y sistemas de modelado de flujo de hidrocarburos de querogenos en una formacion que contiene hidrocarburos | |
| EP4279139A3 (en) | Polymer particles | |
| WO2015088519A3 (en) | Hydrofluoric acid acidizing composition compatible with sensitive metallurgical grades | |
| WO2017007999A8 (en) | Abrasive articles and method of forming same | |
| WO2011153369A3 (en) | Porous glass articles formed using cold work process | |
| JP2016505391A5 (hr) | ||
| EP3883615A4 (en) | METHODS AND COMPOSITIONS FOR ACHIEVING HEMOSTASIS AND STABLE BLOOD CLOT FORMATION | |
| Lawrie et al. | The characterization and impact of microparticles on haemostasis within fresh‐frozen plasma | |
| HUE055345T2 (hu) | Exogén genetikai anyaggal transzfektált vérlemezke és a transzfektált vérlemezekékkel nyert vérlemezke mikrorészecskék, eljárás azok elõállítására és alkalmazására | |
| Guzmán-Uribe et al. | Thrombosis in leukemia: incidence, causes, and practical management | |
| HRP20220892T1 (hr) | Pripravak rmp i postupci upotrebe | |
| WO2016191332A3 (en) | Methods, systems, and compositions for determining blood clot formation, and uses thereof | |
| WO2019023060A3 (en) | NANOPOROUS SUPERABSORBENT PARTICLES | |
| WO2014089442A3 (en) | A composition, an article and a method for the bonding of non-woven substrates | |
| Tripodi et al. | Nontransfusional approach to increased platelet count in patients with cirrhosis and thrombocytopenia |